Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amicidin-β topical solution - 15 mL
Amicidin-β · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| SOC + Amicidin-β topical solution - 15 mL | EXPERIMENTAL | In addition to Standard of Care (SOC), patients will receive Amicidin-β topical solution - 15 mL immediately prior to wound closure/dressing, with rinsing out with saline. |
| SOC + Amicidin-β topical solution - 50 mL - Scheme 1 | EXPERIMENTAL | In addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, with rinsing out with saline |
| SOC + Amicidin-β topical solution - 50 mL - Scheme 2 | EXPERIMENTAL | In addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, without rinsing out with saline |
| SOC | ACTIVE_COMPARATOR | Patients will receive Standard of Care (SOC) only |
| Name | Type | Description |
|---|---|---|
| Amicidin-β topical solution - 15 mL | DRUG | Amicidin-β topical solution for local administration - 15 mL |
| Amicidin-β topical solution - 50 mL | DRUG | Amicidin-β topical solution for local administration - 50 mL |
| Standard of Care (SOC) | DRUG | Per institutional Standard Of Care |
Main Inclusion Criteria: * Body Mass Index between 18.5 kg/square meter and 39.9kg/square meter * Surgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of th...
Amicidin-β is an investigational small molecule being developed for the treatment of surgical wound infections. It is formulated as a topical solution and is currently in Phase 1 clinical development. The drug is being studied in patients with surgical or traumatic wound infections.
Amicidin-β is a small molecule, but its specific molecular target has not been disclosed. The drug is being developed as a topical solution for infectious disease, specifically for surgical wound infections. Its mechanism of action is not publicly detailed at this time.
Amicidin-β is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The drug is currently in Phase 1 clinical trials for the treatment of surgical wound infections.
Amicidin-β is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants to evaluate the drug's safety and efficacy in patients with wound infections.
Amicidin-β is being studied in a Phase 1 clinical trial with the identifier NCT07379684. This trial is titled "A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections" and is currently recruiting participants in the United States. The study plans to enroll 44 patients aged 18 years and older.
Yes, Amicidin-β is also known as Amicidin-β topical solution - 15 mL. This alternative name refers to the specific formulation and packaging of the drug being tested in clinical trials. Both names refer to the same investigational drug product developed by Novo Nordisk.